Investor's Business Daily on MSN
Biotech stocks tumble, with recent winners Moderna, Vaxcyte among the biggest losers
Biotech stocks took a hit Tuesday, with Vaxcyte, Moderna and Revolution Medicines posting some of the steepest losses.
Every year, numerous biotechnology innovations demonstrate promising results in the laboratory. Yet many of them never ...
ArriVent Biopharma said its lung-cancer drug failed to meet long-term goals.
A biotech company has received a £2.5 million funding boost from the Scottish National Investment Bank to support its new ...
An Edinburgh biotech company has received a £2.5 million funding boost from the Scottish National Investment Bank to support ...
ArriVent BioPharma Inc. stocks have been trading down by -58.08 percent amid heightened concern over its latest clinical ...
ArriVent BioPharma Inc.’s stocks have been trading down by -57.66 percent amid heightened concern over its latest clinical ...
The Minister for Environment, Science and Technology, Dr Zanetor Agyeman-Rawlings, has called for the establishment of a ...
Across the ARK Genomic Revolution ETF and the ARK Innovation ETF, Wood bought $6.1 million in Recursion Pharmaceuticals, $1.2 million in Intellia Therapeutics, and $5.3 million in Veracyte.
Dutch haul comes despite European drugmakers and investors warning the region is losing ground.
Using a short lapidated peptide (SLiP) developed by Mimetic Medicines disrupted a crucial voltage-gated sodium channel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results